{"gene":"TERT","run_date":"2026-06-10T10:51:54","timeline":{"discoveries":[{"year":1997,"finding":"hEST2/hTERT (TERT) was identified as the human telomerase catalytic subunit gene based on sequence similarity with lower eukaryote telomerase catalytic subunit genes; its mRNA expression parallels telomerase activity in tumor cells and during immortalization, suggesting it is a rate-limiting determinant of telomerase activity.","method":"Molecular cloning, sequence analysis, expression profiling in telomerase-positive vs. negative cell lines and tissues","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — foundational cloning and expression analysis replicated in the same study and confirmed by subsequent ectopic expression experiments (PMID:9528864); widely replicated across the field","pmids":["9288757"],"is_preprint":false},{"year":1998,"finding":"Ectopic expression of epitope-tagged hTERT in telomerase-negative human cells reconstituted telomerase activity to levels comparable to immortal cells, and the expressed hTERT protein co-purified with cellular telomerase activity, establishing hTERT as the rate-limiting catalytic subunit of the telomerase holoenzyme.","method":"Ectopic expression of tagged hTERT, telomerase activity assay (TRAP), co-purification of hTERT with telomerase activity","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct reconstitution of telomerase activity by ectopic expression plus co-purification; functional validation in multiple cell lines","pmids":["9528864"],"is_preprint":false},{"year":2001,"finding":"Xenopus TERT (xTERT) reconstituted active telomerase in vitro when co-expressed with the Xenopus telomerase RNA (xTR) in a cell-free system, confirming that TERT is the catalytic reverse transcriptase subunit that directly assembles with the RNA component to form active telomerase. xTERT expression levels were shown to be the primary mechanism regulating telomerase activity during Xenopus development.","method":"In vitro reconstitution of telomerase activity using recombinant xTERT and xTR in rabbit reticulocyte lysate; telomerase activity assays across developmental stages","journal":"Gene","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro reconstitution with defined components; orthologous vertebrate TERT","pmids":["11602347"],"is_preprint":false},{"year":2004,"finding":"In budding yeast (S. cerevisiae), a specific stem-loop hairpin within the telomerase RNA TLC1 is required for interaction with the Est2 (TERT ortholog) reverse transcriptase protein. Replacement of a 95-nucleotide region required for Est2 interaction with a 39-nucleotide pseudoknot from a distantly related telomerase RNA produced functional telomerase, indicating that Est2 associates with the RNA via a structured region rather than specific sequences.","method":"Mutagenesis of TLC1 RNA stem-loop structures; genetic complementation assays for telomere maintenance; RNA-protein interaction studies","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis combined with functional reconstitution in yeast; multiple orthogonal methods","pmids":["15314178"],"is_preprint":false},{"year":2009,"finding":"Human TERT interacts with RMRP RNA (the RNA component of mitochondrial RNA processing endoribonuclease) to form a distinct ribonucleoprotein complex with RNA-dependent RNA polymerase (RdRP) activity, producing double-stranded RNAs that can be processed into siRNA in a Dicer-dependent manner. This identifies a mammalian RdRP activity for TERT independent of telomere synthesis.","method":"Co-immunoprecipitation of TERT with RMRP RNA; in vitro RdRP activity assay; Dicer-dependent siRNA processing assay","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — biochemical reconstitution of RdRP activity, Co-IP, and functional siRNA processing assay; published in Nature with multiple orthogonal methods","pmids":["19701182"],"is_preprint":false},{"year":2013,"finding":"Recurrent somatic point mutations in the TERT core promoter (-124C>T and -146C>T) in melanoma generate de novo consensus binding motifs for ETS transcription factors and increase transcriptional activity from the TERT promoter by two- to fourfold in reporter assays, providing a mechanism for cancer-specific TERT re-expression.","method":"Systematic cancer genome sequencing; luciferase reporter assays of mutant vs. wild-type TERT promoter; ETS motif analysis","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — reporter assays with functional validation; independently replicated by two concurrent papers (PMID:23348503 and PMID:23348506)","pmids":["23348506","23348503"],"is_preprint":false},{"year":2015,"finding":"TERT promoter mutations in urothelial cancer correlate with higher TERT mRNA levels, TERT protein levels, telomerase enzymatic activity, and telomere length compared to wild-type promoter cells, directly linking promoter mutation to functional telomerase upregulation.","method":"Analysis of 23 human UC cell lines: TERT mRNA quantification, TERT protein detection, telomerase TRAP assay, telomere length measurement","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal functional readouts (mRNA, protein, enzymatic activity, telomere length) in a well-defined cell line panel","pmids":["25722414"],"is_preprint":false},{"year":2015,"finding":"TERT promoter mutations lead to monoallelic expression of TERT in human cancer cells; hotspot TERT promoter mutations, without exception, re-activate only one allele as shown by deep RNA sequencing with allele-specific analysis.","method":"Deep RNA sequencing with allele-specific variant analysis in human cancer cell lines","journal":"Oncogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — single lab, allele-specific RNA-seq; technically rigorous but not independently replicated in this study","pmids":["26657580"],"is_preprint":false},{"year":2016,"finding":"Nrf2 and TERT form a regulatory loop in glioblastoma: TERT knockdown abrogates Nrf2 levels, while ectopic Nrf2 expression increases TERT expression. TERT inhibition (by drug, siRNA, or dominant-negative TERT) suppresses expression and activity of pentose phosphate pathway enzymes G6PD and Transketolase, and leads to glycogen accumulation, placing TERT as a regulator of metabolic flux.","method":"siRNA knockdown, dominant-negative TERT overexpression, pharmacological inhibition (Costunolide), ectopic Nrf2 expression, enzyme activity assays, xenograft mouse model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple loss-of-function approaches plus rescue experiment, single lab, with in vivo validation","pmids":["27148686"],"is_preprint":false},{"year":2018,"finding":"DNA hypermethylation of THOR (a 433-bp region immediately upstream of the TERT core promoter, containing 52 CpG sites) counteracts its repressive function on TERT promoter activity and constitutes a prevalent cancer-associated epigenetic mechanism of TERT upregulation independent of TERT promoter mutations.","method":"Reporter assays with methylated/unmethylated THOR constructs; bisulfite sequencing/methylation analysis in 1,352 human tumors; functional promoter activity assays","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — reporter assays plus large-scale tumor methylation analysis with functional validation; multiple orthogonal methods","pmids":["30358567"],"is_preprint":false},{"year":2018,"finding":"AGO2 promotes telomerase activity and stimulates physical association between TERT and TERC; AGO2 depletion results in shorter telomeres and lower proliferation. AGO2 interacts with TERC and a small RNA (terc-sRNA) derived from the H/ACA box of TERC, and overexpression of terc-sRNA alone is sufficient to enhance telomerase activity.","method":"Gain- and loss-of-function approaches (AGO2 knockdown/overexpression); Co-IP of AGO2 with TERC; telomerase activity assay; telomere length measurement; in vitro and in vivo proliferation assays","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal functional assays with Co-IP, single lab with multiple orthogonal methods","pmids":["30591524"],"is_preprint":false},{"year":2019,"finding":"ETS1 links BRAFV600E oncogenic signaling to TERT promoter activity in double-mutant (BRAFV600E + TERT promoter mutation) glioma: BRAF inhibition reduces ETS1 expression and phosphorylation, decreases TERT promoter activity and TERT expression exclusively in double-mutant cells. ChIP confirmed ETS1 binding to the mutant TERT promoter.","method":"qRT-PCR, chromatin immunoprecipitation (ChIP), Western blot, luciferase reporter assays, siRNA knockdown, BRAF inhibitor treatment in glioma cell lines","journal":"Acta neuropathologica communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter assays plus knockdown, single lab, multiple orthogonal methods","pmids":["31391125"],"is_preprint":false},{"year":2020,"finding":"TERT promoter mutations create binding sites for the GABPB1L-isoform-containing GABP complex; increased binding of this specific complex to the mutant TERT promoter drives TERT reactivation and telomere maintenance. TERT promoter mutant GBM cells exhibit critical dependence on GABPB1L for proliferation, and GABPB1L knockdown combined with temozolomide impairs DNA damage response and reduces GBM tumor growth in vivo.","method":"GABPB1L-specific binding assays, GABPB1L knockdown (genetic/inducible), in vivo intracranial GBM tumor growth, combination with temozolomide chemotherapy","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic binding studies, inducible genetic knockdown, in vivo tumor model, multiple orthogonal methods in a single rigorous study","pmids":["33758097"],"is_preprint":false},{"year":2020,"finding":"CRISPR/Cas9-mediated base editing of the -124C>T TERT promoter mutation back to wild-type -124C blocked ETS family transcription factor binding to the TERT promoter, reduced TERT transcription and protein expression, and induced cancer cell senescence and proliferative arrest; local AAV delivery of the base editor inhibited growth of TERT promoter-mutant gliomas in vivo.","method":"Programmable adenine base editing (CjABE), sgRNA-guided CRISPR interference, qRT-PCR for TERT expression, Western blot for TERT protein, senescence assays, in vivo glioma xenograft model with AAV delivery","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — precision base editing with functional readouts (transcription, protein, senescence) plus in vivo validation; multiple orthogonal methods","pmids":["32066906"],"is_preprint":false},{"year":2020,"finding":"NCOA3 binds to the TERT promoter at the -234 to -144 region, recruits SP1, and transcriptionally activates TERT expression in hepatocellular carcinoma. NCOA3 knockdown suppresses HCC cell growth and is rescued by TERT overexpression, placing TERT downstream of the NCOA3-SP1 axis.","method":"NCOA3 knockdown/overexpression, TERT overexpression rescue, TERT promoter binding assays (ChIP-like), in vitro and in vivo tumor growth assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter binding assay, knockdown/rescue epistasis, single lab with multiple functional assays","pmids":["33239622"],"is_preprint":false},{"year":2020,"finding":"TERT can transcriptionally activate a subclass of endogenous retroviruses (ERVs) independent of its telomerase activity, generating double-stranded RNAs sensed by the RIG-1/MDA5-MAVS pathway to trigger interferon signaling; TERT-induced ERV/interferon signaling stimulates CXCL10 chemokine expression, promoting infiltration of suppressive T-cell populations (CD4+ and FOXP3+) in tumors.","method":"ssGSEA across 9,264 tumor samples; TERT overexpression/knockdown; telomerase-dead TERT mutant; dsRNA detection; RIG-1/MDA5-MAVS pathway analysis; T-cell infiltration analysis","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — telomerase-dead mutant distinguishes telomere-independent function; multiple pathway analyses; single lab","pmids":["35107856"],"is_preprint":false},{"year":2021,"finding":"Nuclear retention of TERT mRNA is driven by intron retention; specific introns are robustly retained in nuclear TERT transcripts (shown by single-molecule RNA FISH), and splicing of these retained introns occurs during mitosis. Blocking intron excision using RNA-targeting thiomorpholino antisense oligonucleotides forces nuclear retention and significantly affects cell viability.","method":"Single-molecule RNA FISH, RNA-targeting thiomorpholino antisense oligonucleotides (blocking intron excision), cell viability assays, splicing analysis","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — single-molecule FISH for localization, antisense oligonucleotide functional perturbation; single lab with multiple orthogonal methods","pmids":["34083519"],"is_preprint":false},{"year":2021,"finding":"RBM10 promotes exclusion of exons 7 and 8 from hTERT pre-mRNA, switching production from full-length active hTERT (hTERT-FL) to a functionless isoform (hTERT-s), thereby suppressing telomerase activity and subsequent telomere shortening. RNA immunoprecipitation and RNA pull-down confirmed direct RBM10-hTERT RNA interaction.","method":"RNA immunoprecipitation (RNA-IP), RNA pull-down assay, gain/loss-of-function experiments, telomerase activity assay, xenograft tumor growth assay","journal":"American journal of cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA-IP and pull-down establish direct interaction; functional splicing switch confirmed by gain/loss-of-function; single lab","pmids":["33520366"],"is_preprint":false},{"year":2021,"finding":"Missense TERT rare variants in MDS patients impair domain-specific functions including catalysis, protein-RNA interactions, and recruitment to telomeres, as assessed by a cell-based telomere elongation assay. A homology model of human TERT bound to shelterin protein TPP1 was used to infer structural impact of variants.","method":"Cloning of all rare missense variants; cell-based telomere elongation assay; homology structural modeling of TERT-TPP1 interaction","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systematic cell-based functional assays across many variants; homology model provides structural context; single lab","pmids":["34019641"],"is_preprint":false},{"year":2022,"finding":"GABP (specifically the GABPB1L isoform complex) couples EGFR-AMPK oncogenic signaling to TERT expression selectively from the mutant TERT promoter in glioblastoma; proliferation arrest decreases TERT expression in a GABP-dependent manner, and EGFR-AMPK signaling promotes telomerase activity and maintains telomere length.","method":"Copy number/mRNA/protein correlation analysis, pharmacologic EGFR inhibition, genetic GABP perturbation, AMPK pathway analysis, telomerase activity assay, telomere length measurement","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacologic and genetic perturbations with pathway epistasis; single lab, multiple orthogonal methods","pmids":["36130485"],"is_preprint":false},{"year":2022,"finding":"TPP1 (ACD) promoter variants co-occurring with TERT promoter mutations in melanoma create or modify ETS transcription factor binding sites, increase TPP1 expression, and function together with TERT to synergistically lengthen telomeres, demonstrating that TERT promoter mutation alone is insufficient for telomere maintenance and requires cooperation with TPP1 upregulation.","method":"Genomic sequencing of melanoma samples, reporter assays for ACD promoter variants, TPP1/TERT expression analysis, telomere length measurement","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — reporter assays plus telomere functional readout, mechanistic epistasis between TERT and TPP1, multiple orthogonal methods","pmids":["36356143"],"is_preprint":false},{"year":2022,"finding":"KLF4 directly binds to the TERT promoter region (shown by ChIP) in alveolar epithelial cells and regulates TERT transcription; KLF4 siRNA knockdown reduces TERT expression and telomerase activity, while KLF4 overexpression increases them. In vivo, AAV-mediated KLF4 overexpression in alveolar epithelial cells protects TERT expression and suppresses pulmonary fibrosis.","method":"ChIP assay, siRNA knockdown, KLF4 overexpression, telomerase activity assay, AAV-mediated in vivo overexpression in mouse model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP establishes direct promoter binding, gain/loss-of-function with in vivo validation; single lab","pmids":["35508454"],"is_preprint":false},{"year":2024,"finding":"A TERT activator compound (TAC) upregulates TERT transcription via the MEK/ERK/AP-1 signaling cascade. TAC-induced TERT elevation promotes telomere synthesis and silences p16INK4a expression via upregulation of DNMT3B-mediated promoter hypermethylation, reducing senescence markers, inflammatory cytokines, and neuroinflammation in aged mice while preserving cognitive function.","method":"TERT activator compound treatment; MEK/ERK/AP-1 pathway inhibitor epistasis; DNMT3B analysis; telomere synthesis assay; cellular senescence and p16INK4a measurements; in vivo aged mouse model","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — pathway epistasis with inhibitors, mechanistic downstream chromatin readout (DNMT3B-p16), in vivo validation with multiple aging hallmarks; published in Cell","pmids":["38908367"],"is_preprint":false},{"year":2020,"finding":"TERT overexpression increases DNMT1 levels and DAC (decitabine) sensitivity via a telomerase-independent mechanism in glioma cells; p21 knockdown leads to TERT upregulation, and DNMT1 RNA inhibition abrogates DAC response in TERT-proficient cells, placing TERT upstream of DNMT1 in a p21-TERT-DNMT1 axis.","method":"TERT overexpression, p21 knockdown (siRNA), DNMT1 RNAi, DAC treatment, RNA sequencing, KEGG enrichment analysis","journal":"Neuro-oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with multiple knockdown/overexpression experiments and transcriptome analysis; single lab","pmids":["32882013"],"is_preprint":false},{"year":2020,"finding":"Genomic and epigenomic inactivation of EBF1 (via DNA methylation, dominant-negative mutations, or genomic deletion of EBF1 binding sites near the TERT promoter) de-represses TERT transcription in gastric cancer, identifying EBF1 as a direct TERT transcriptional repressor.","method":"Comprehensive genomic and epigenomic analysis of primary GCs; ChIP for EBF1 binding at TERT promoter; reporter assays; EBF1 knockdown/overexpression functional assays in vitro and in vivo","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP, reporter assays, functional epistasis with in vivo validation; multiple orthogonal methods in a single rigorous study","pmids":["32364535"],"is_preprint":false},{"year":2021,"finding":"TERT silencing (directly or via GABPB1 knockdown) in TERT promoter mutant glioblastoma reduces pentose phosphate pathway flux, glucose-6-phosphate dehydrogenase activity, NADPH, lactate production, glycolytic flux, and glutathione levels, defining metabolic consequences of TERT suppression detectable by MRS.","method":"TERT and GABPB1 siRNA knockdown, 1H and hyperpolarized 13C MRS metabolic imaging, enzyme activity assays (G6PD), NADPH/NADH measurement, in vivo tumor imaging","journal":"Neuro-oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple metabolic assays with in vivo imaging; single lab with orthogonal MRS methods","pmids":["35460557"],"is_preprint":false}],"current_model":"TERT is the catalytic reverse transcriptase subunit of the telomerase holoenzyme that assembles with the RNA component TERC to synthesize telomeric DNA repeats at chromosome ends; its expression is the rate-limiting determinant of telomerase activity, it is transcriptionally controlled by a network of factors including MYC, ETS/GABP (recruited by hotspot promoter mutations at -124/-146), KLF4, EBF1 (repressor), NCOA3-SP1, and epigenetic mechanisms (THOR methylation, chromatin accessibility), and it also possesses non-canonical functions including RdRP activity (via RMRP RNA complex), regulation of the pentose phosphate pathway and DNMT1 levels, ERV-driven immunosuppressive signaling, and mitochondrial protection against oxidative stress."},"narrative":{"mechanistic_narrative":"TERT is the catalytic reverse transcriptase subunit of telomerase, the ribonucleoprotein enzyme that synthesizes telomeric DNA repeats at chromosome ends, and its expression level is the rate-limiting determinant of telomerase activity during immortalization and tumorigenesis [PMID:9288757, PMID:9528864]. TERT directly assembles with the telomerase RNA component to form active enzyme, an interaction that depends on a structured region of the RNA rather than a specific sequence, as established by in vitro reconstitution and RNA-mutagenesis in vertebrate and yeast systems [PMID:11602347, PMID:15314178]. Because TERT is normally silenced in somatic cells, its cancer-specific re-expression is achieved chiefly through transcriptional deregulation: recurrent -124C>T and -146C>T promoter mutations create de novo ETS binding motifs and drive monoallelic reactivation, raising TERT mRNA, protein, telomerase activity, and telomere length [PMID:23348506, PMID:23348503, PMID:25722414, PMID:26657580]. These mutant promoters are read out by the GABPB1L-isoform GABP complex and by ETS1, coupling oncogenic BRAF and EGFR-AMPK signaling to selective TERT induction and creating a dependence on GABPB1L for tumor growth that is reversible by base-editing the mutation back to wild-type [PMID:31391125, PMID:33758097, PMID:32066906, PMID:36130485]. A parallel layer of regulation operates through an activating network and repressive controls: KLF4, the NCOA3-SP1 axis, and MEK/ERK/AP-1 signaling activate TERT, while EBF1 acts as a direct repressor and THOR-region DNA methylation neutralizes repression to upregulate TERT independently of promoter mutation [PMID:30358567, PMID:33239622, PMID:35508454, PMID:38908367, PMID:32364535]. Cooperation with the shelterin component TPP1, whose promoter variants co-occur with TERT promoter mutations, is required for productive telomere lengthening [PMID:36356143]. Post-transcriptional control further tunes TERT through intron retention that confines transcripts to the nucleus until mitotic splicing and through RBM10-driven exon skipping that switches output toward a nonfunctional isoform [PMID:34083519, PMID:33520366]. Beyond telomere synthesis, TERT carries out telomerase-independent functions: it forms an RNA-dependent RNA polymerase complex with RMRP RNA generating Dicer-processed siRNAs [PMID:19701182], transcriptionally activates endogenous retroviruses to trigger RIG-1/MDA5-MAVS interferon and CXCL10 signaling that shapes the tumor immune microenvironment [PMID:35107856], sustains pentose phosphate pathway flux and an Nrf2 regulatory loop [PMID:27148686, PMID:35460557], and acts upstream of DNMT1 and DNMT3B to control DNA methylation and senescence programs [PMID:38908367, PMID:32882013]. Rare missense TERT variants in myelodysplastic syndrome impair catalysis, protein-RNA interaction, and telomere recruitment [PMID:34019641].","teleology":[{"year":1998,"claim":"Established that TERT is itself the rate-limiting catalytic subunit of telomerase rather than a correlated marker, by showing its expression alone reconstitutes enzyme activity.","evidence":"Cloning and expression profiling, then ectopic expression of tagged hTERT with TRAP assays and co-purification in telomerase-negative cells","pmids":["9288757","9528864"],"confidence":"High","gaps":["Did not define the structural basis of TERT-RNA assembly","Did not address how TERT is silenced in somatic cells"]},{"year":2004,"claim":"Defined how TERT engages telomerase RNA, showing assembly depends on a structured RNA region rather than specific sequence.","evidence":"In vitro reconstitution of vertebrate TERT with telomerase RNA in reticulocyte lysate, and stem-loop mutagenesis of yeast TLC1 with genetic complementation","pmids":["11602347","15314178"],"confidence":"High","gaps":["Human TERT-TERC contact map not resolved at atomic level","Did not address regulation of human TERT expression"]},{"year":2015,"claim":"Identified the dominant mechanism of cancer-specific TERT reactivation, showing hotspot promoter mutations create ETS motifs that monoallelically upregulate telomerase and lengthen telomeres.","evidence":"Cancer genome sequencing, luciferase reporter assays, and a urothelial cell-line panel measuring mRNA, protein, TRAP activity, telomere length, plus allele-specific RNA-seq","pmids":["23348506","23348503","25722414","26657580"],"confidence":"High","gaps":["Monoallelic specificity mechanism not fully explained","Which trans-factors read the mutant motif left for later work"]},{"year":2009,"claim":"Revealed a telomerase-independent activity by showing TERT forms an RdRP complex with RMRP RNA producing Dicer-processed siRNAs.","evidence":"Co-IP of TERT with RMRP RNA, in vitro RdRP assay, and Dicer-dependent siRNA processing","pmids":["19701182"],"confidence":"High","gaps":["Physiological targets of the siRNAs not defined","Relationship to telomerase complex assembly unclear"]},{"year":2020,"claim":"Showed which transcription factor complex executes promoter-mutant reactivation and that it is a therapeutic dependency, by linking the GABPB1L-GABP complex and ETS1 to oncogenic signaling and reverting the mutation by base editing.","evidence":"GABPB1L-specific binding and inducible knockdown, ChIP for ETS1, BRAF inhibition, and AAV-delivered adenine base editor in glioma models in vivo","pmids":["33758097","31391125","32066906"],"confidence":"High","gaps":["Generality across non-glioma promoter-mutant tumors not fully mapped","Long-term safety of base-editing approach untested"]},{"year":2020,"claim":"Expanded the transcriptional control network beyond promoter mutations, identifying activators (KLF4, NCOA3-SP1), a direct repressor (EBF1), and THOR methylation as a mutation-independent epigenetic route.","evidence":"ChIP, reporter assays, knockdown/rescue epistasis, large-scale tumor methylation analysis, and in vivo models across HCC, gastric, and lung tissue","pmids":["30358567","33239622","35508454","32364535"],"confidence":"High","gaps":["Hierarchy and combinatorial logic among these factors unresolved","Tissue specificity of each control mechanism incompletely defined"]},{"year":2022,"claim":"Showed that promoter-mutant TERT upregulation is insufficient alone, requiring cooperative TPP1 upregulation for telomere lengthening.","evidence":"Melanoma genomic sequencing, ACD/TPP1 promoter reporter assays, and telomere length measurement","pmids":["36356143"],"confidence":"High","gaps":["Whether other shelterin components similarly cooperate is unaddressed","Mechanism of TERT-TPP1 functional synergy at telomeres not detailed"]},{"year":2022,"claim":"Defined post-transcriptional control of TERT through nuclear intron retention with mitotic splicing and RBM10-driven exon skipping toward a nonfunctional isoform.","evidence":"Single-molecule RNA FISH, antisense oligonucleotide blocking of intron excision, RNA-IP and pull-down, and telomerase activity assays","pmids":["34083519","33520366"],"confidence":"Medium","gaps":["Signals coupling splicing to cell cycle not identified","Single-lab findings not independently replicated"]},{"year":2024,"claim":"Characterized telomerase-independent and downstream metabolic/epigenetic roles of TERT, linking it to PPP flux, an Nrf2 loop, ERV-driven interferon signaling, DNMT control, and senescence suppression.","evidence":"Loss/gain-of-function with telomerase-dead mutants, MRS metabolic imaging, pathway inhibitor epistasis, transcriptomics, and in vivo tumor and aging models","pmids":["27148686","35107856","35460557","32882013","38908367"],"confidence":"Medium","gaps":["Direct molecular targets of TERT in these non-canonical roles not defined","Mostly single-lab studies with limited cross-validation"]},{"year":2021,"claim":"Connected TERT to human disease by showing rare missense variants impair catalysis, RNA binding, and telomere recruitment in MDS patients.","evidence":"Cell-based telomere elongation assays across all rare variants and homology modeling of TERT-TPP1","pmids":["34019641"],"confidence":"Medium","gaps":["Genotype-phenotype correlation in patients not fully established","Structural inferences based on homology model rather than experimental structure"]},{"year":null,"claim":"How the diverse telomerase-independent functions of TERT (RdRP, ERV/interferon signaling, metabolic and DNMT regulation) are mechanistically integrated with its canonical reverse transcriptase activity and partitioned across subcellular compartments remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No unified model linking canonical and non-canonical activities","Compartment-specific TERT pools and their distinct partners not defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[1,2,4]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[3,4]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[1,2]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[15,23]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[16]},{"term_id":"GO:0005694","term_label":"chromosome","supporting_discovery_ids":[1,6]}],"pathway":[{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[0,1,6]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[5,12,24]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[5,13,18]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[8,25]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[15]}],"complexes":["telomerase holoenzyme","TERT-RMRP RdRP complex"],"partners":["TERC","RMRP","TPP1","AGO2","GABPB1L","RBM10","SP1","NCOA3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O14746","full_name":"Telomerase reverse transcriptase","aliases":["HEST2","Telomerase catalytic subunit","Telomerase-associated protein 2","TP2"],"length_aa":1132,"mass_kda":127.0,"function":"Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. Active in progenitor and cancer cells. Inactive, or very low activity, in normal somatic cells. Catalytic component of the teleromerase holoenzyme complex whose main activity is the elongation of telomeres by acting as a reverse transcriptase that adds simple sequence repeats to chromosome ends by copying a template sequence within the RNA component of the enzyme. Catalyzes the RNA-dependent extension of 3'-chromosomal termini with the 6-nucleotide telomeric repeat unit, 5'-TTAGGG-3'. The catalytic cycle involves primer binding, primer extension and release of product once the template boundary has been reached or nascent product translocation followed by further extension. More active on substrates containing 2 or 3 telomeric repeats. Telomerase activity is regulated by a number of factors including telomerase complex-associated proteins, chaperones and polypeptide modifiers. Modulates Wnt signaling. Plays important roles in aging and antiapoptosis","subcellular_location":"Nucleus, nucleolus; Nucleus, nucleoplasm; Nucleus; Chromosome, telomere; Cytoplasm; Nucleus, PML body","url":"https://www.uniprot.org/uniprotkb/O14746/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TERT","classification":"Not Classified","n_dependent_lines":21,"n_total_lines":1208,"dependency_fraction":0.0173841059602649},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TERT","total_profiled":1310},"omim":[{"mim_id":"621284","title":"GA-BINDING PROTEIN TRANSCRIPTION FACTOR, SUBUNIT BETA-2; GABPB2","url":"https://www.omim.org/entry/621284"},{"mim_id":"620929","title":"MOB KINASE ACTIVATOR 3A; MOB3A","url":"https://www.omim.org/entry/620929"},{"mim_id":"619766","title":"YLP MOTIF-CONTAINING PROTEIN 1; YLPM1","url":"https://www.omim.org/entry/619766"},{"mim_id":"619388","title":"TETRATRICOPEPTIDE REPEAT DOMAIN-CONTAINING PROTEIN 17; TTC17","url":"https://www.omim.org/entry/619388"},{"mim_id":"619387","title":"CILIOGENESIS-ASSOCIATED TTC17-INTERACTING PROTEIN; CATIP","url":"https://www.omim.org/entry/619387"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nuclear speckles","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Not detected","tissue_distribution":"Not detected","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TERT"},"hgnc":{"alias_symbol":["TRT","TP2","TCS1","hEST2","EST2"],"prev_symbol":[]},"alphafold":{"accession":"O14746","domains":[{"cath_id":"-","chopping":"9-176","consensus_level":"high","plddt":90.2374,"start":9,"end":176},{"cath_id":"1.10.132.70","chopping":"326-370_385-414_446-523_536-581","consensus_level":"medium","plddt":92.5726,"start":326,"end":581},{"cath_id":"-","chopping":"600-672_737-827","consensus_level":"high","plddt":82.0894,"start":600,"end":827},{"cath_id":"1.10.357.90","chopping":"943-1128","consensus_level":"high","plddt":91.9138,"start":943,"end":1128}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O14746","model_url":"https://alphafold.ebi.ac.uk/files/AF-O14746-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O14746-F1-predicted_aligned_error_v6.png","plddt_mean":80.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TERT","jax_strain_url":"https://www.jax.org/strain/search?query=TERT"},"sequence":{"accession":"O14746","fasta_url":"https://rest.uniprot.org/uniprotkb/O14746.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O14746/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O14746"}},"corpus_meta":[{"pmid":"9288757","id":"PMC_9288757","title":"hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization.","date":"1997","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/9288757","citation_count":1596,"is_preprint":false},{"pmid":"23348506","id":"PMC_23348506","title":"Highly recurrent TERT promoter mutations in human melanoma.","date":"2013","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/23348506","citation_count":1481,"is_preprint":false},{"pmid":"23348503","id":"PMC_23348503","title":"TERT promoter mutations in familial and sporadic melanoma.","date":"2013","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/23348503","citation_count":1470,"is_preprint":false},{"pmid":"9528864","id":"PMC_9528864","title":"Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase.","date":"1998","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9528864","citation_count":356,"is_preprint":false},{"pmid":"26733501","id":"PMC_26733501","title":"TERT promoter mutations in thyroid cancer.","date":"2016","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26733501","citation_count":346,"is_preprint":false},{"pmid":"19701182","id":"PMC_19701182","title":"An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA.","date":"2009","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/19701182","citation_count":309,"is_preprint":false},{"pmid":"25722414","id":"PMC_25722414","title":"Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.","date":"2015","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/25722414","citation_count":265,"is_preprint":false},{"pmid":"26941407","id":"PMC_26941407","title":"Understanding TERT Promoter Mutations: A Common Path to Immortality.","date":"2016","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/26941407","citation_count":240,"is_preprint":false},{"pmid":"33329574","id":"PMC_33329574","title":"TERT-Regulation and Roles in Cancer Formation.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33329574","citation_count":232,"is_preprint":false},{"pmid":"24657534","id":"PMC_24657534","title":"TERT promoter mutations in cancer development.","date":"2013","source":"Current opinion in genetics & development","url":"https://pubmed.ncbi.nlm.nih.gov/24657534","citation_count":191,"is_preprint":false},{"pmid":"28342451","id":"PMC_28342451","title":"TERT promoter mutations in telomere biology.","date":"2016","source":"Mutation research. Reviews in mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/28342451","citation_count":157,"is_preprint":false},{"pmid":"30358567","id":"PMC_30358567","title":"DNA hypermethylation within TERT promoter upregulates TERT expression in cancer.","date":"2018","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/30358567","citation_count":145,"is_preprint":false},{"pmid":"29802247","id":"PMC_29802247","title":"The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29802247","citation_count":136,"is_preprint":false},{"pmid":"32066906","id":"PMC_32066906","title":"Programmable base editing of mutated TERT promoter inhibits brain tumour growth.","date":"2020","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/32066906","citation_count":127,"is_preprint":false},{"pmid":"27438857","id":"PMC_27438857","title":"Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications.","date":"2016","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/27438857","citation_count":111,"is_preprint":false},{"pmid":"17266519","id":"PMC_17266519","title":"Chemoprotective and carcinogenic effects of tert-butylhydroquinone and its metabolites.","date":"2007","source":"Current drug metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/17266519","citation_count":108,"is_preprint":false},{"pmid":"27148686","id":"PMC_27148686","title":"Nrf2-driven TERT regulates pentose phosphate pathway in glioblastoma.","date":"2016","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/27148686","citation_count":98,"is_preprint":false},{"pmid":"25225064","id":"PMC_25225064","title":"Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer.","date":"2014","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/25225064","citation_count":97,"is_preprint":false},{"pmid":"20478107","id":"PMC_20478107","title":"Variation at the TERT locus and predisposition for cancer.","date":"2010","source":"Expert reviews in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20478107","citation_count":93,"is_preprint":false},{"pmid":"33800183","id":"PMC_33800183","title":"TERT Promoter Alterations in Glioblastoma: A Systematic Review.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33800183","citation_count":83,"is_preprint":false},{"pmid":"38278800","id":"PMC_38278800","title":"The regulations of telomerase reverse transcriptase (TERT) in cancer.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38278800","citation_count":82,"is_preprint":false},{"pmid":"25809917","id":"PMC_25809917","title":"Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer.","date":"2015","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25809917","citation_count":82,"is_preprint":false},{"pmid":"28271343","id":"PMC_28271343","title":"New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.","date":"2017","source":"Current neurology and neuroscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/28271343","citation_count":81,"is_preprint":false},{"pmid":"26657580","id":"PMC_26657580","title":"TERT promoter mutations and monoallelic activation of TERT in cancer.","date":"2015","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/26657580","citation_count":80,"is_preprint":false},{"pmid":"3542758","id":"PMC_3542758","title":"Toxicology of tert-butylhydroquinone (TBHQ).","date":"1986","source":"Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association","url":"https://pubmed.ncbi.nlm.nih.gov/3542758","citation_count":78,"is_preprint":false},{"pmid":"30696697","id":"PMC_30696697","title":"TERT gene: its function and dysregulation in cancer.","date":"2019","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30696697","citation_count":77,"is_preprint":false},{"pmid":"15134874","id":"PMC_15134874","title":"Microbial degradation of methyl tert-butyl ether and tert-butyl alcohol in the subsurface.","date":"2004","source":"Journal of contaminant hydrology","url":"https://pubmed.ncbi.nlm.nih.gov/15134874","citation_count":77,"is_preprint":false},{"pmid":"26336998","id":"PMC_26336998","title":"TERT promoter mutations in primary liver tumors.","date":"2015","source":"Clinics and research in hepatology and gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/26336998","citation_count":76,"is_preprint":false},{"pmid":"38908367","id":"PMC_38908367","title":"TERT activation targets DNA methylation and multiple aging hallmarks.","date":"2024","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/38908367","citation_count":71,"is_preprint":false},{"pmid":"28057768","id":"PMC_28057768","title":"TERT biology and function in cancer: beyond immortalisation.","date":"2017","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/28057768","citation_count":68,"is_preprint":false},{"pmid":"23975423","id":"PMC_23975423","title":"Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23975423","citation_count":66,"is_preprint":false},{"pmid":"28184371","id":"PMC_28184371","title":"Transcriptional Regulation of Telomerase Reverse Transcriptase (TERT) by MYC.","date":"2017","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/28184371","citation_count":65,"is_preprint":false},{"pmid":"26461266","id":"PMC_26461266","title":"Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC.","date":"2015","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/26461266","citation_count":61,"is_preprint":false},{"pmid":"29599449","id":"PMC_29599449","title":"Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis.","date":"2018","source":"Nature reviews. Urology","url":"https://pubmed.ncbi.nlm.nih.gov/29599449","citation_count":60,"is_preprint":false},{"pmid":"26902827","id":"PMC_26902827","title":"TERT Promoter Mutations in Thyroid Cancer.","date":"2016","source":"Hormones & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26902827","citation_count":59,"is_preprint":false},{"pmid":"32163830","id":"PMC_32163830","title":"TERT promoter mutations and telomeres during tumorigenesis.","date":"2020","source":"Current opinion in genetics & development","url":"https://pubmed.ncbi.nlm.nih.gov/32163830","citation_count":57,"is_preprint":false},{"pmid":"31284662","id":"PMC_31284662","title":"Telomerase Reverse Transcriptase (TERT) in Action: Cross-Talking with Epigenetics.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31284662","citation_count":55,"is_preprint":false},{"pmid":"29985536","id":"PMC_29985536","title":"TERT promoter mutations in solitary fibrous tumour.","date":"2018","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/29985536","citation_count":54,"is_preprint":false},{"pmid":"28974544","id":"PMC_28974544","title":"TERT structural rearrangements in metastatic pheochromocytomas.","date":"2017","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28974544","citation_count":52,"is_preprint":false},{"pmid":"32227259","id":"PMC_32227259","title":"Correlation between IDH, ATRX, and TERT promoter mutations in glioma.","date":"2020","source":"Brain tumor pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32227259","citation_count":51,"is_preprint":false},{"pmid":"32849278","id":"PMC_32849278","title":"Telomerase Reverse Transcriptase (TERT) Regulation in Thyroid Cancer: A Review.","date":"2020","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32849278","citation_count":50,"is_preprint":false},{"pmid":"32204305","id":"PMC_32204305","title":"The Solo Play of TERT Promoter Mutations.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32204305","citation_count":47,"is_preprint":false},{"pmid":"26545048","id":"PMC_26545048","title":"Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1.","date":"2015","source":"CNS oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26545048","citation_count":47,"is_preprint":false},{"pmid":"34083519","id":"PMC_34083519","title":"Nuclear compartmentalization of TERT mRNA and TUG1 lncRNA is driven by intron retention.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34083519","citation_count":45,"is_preprint":false},{"pmid":"33758097","id":"PMC_33758097","title":"Cancer-specific loss of TERT activation sensitizes glioblastoma to DNA damage.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33758097","citation_count":44,"is_preprint":false},{"pmid":"29695835","id":"PMC_29695835","title":"Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/29695835","citation_count":44,"is_preprint":false},{"pmid":"25301727","id":"PMC_25301727","title":"TERT promoter mutations and gene amplification: promoting TERT expression in Merkel cell carcinoma.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25301727","citation_count":43,"is_preprint":false},{"pmid":"34019641","id":"PMC_34019641","title":"The clinical and functional effects of TERT variants in myelodysplastic syndrome.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/34019641","citation_count":42,"is_preprint":false},{"pmid":"35107856","id":"PMC_35107856","title":"TERT activates endogenous retroviruses to promote an immunosuppressive tumour microenvironment.","date":"2022","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/35107856","citation_count":42,"is_preprint":false},{"pmid":"15314178","id":"PMC_15314178","title":"Structural elements required for association of the Saccharomyces cerevisiae telomerase RNA with the Est2 reverse transcriptase.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15314178","citation_count":41,"is_preprint":false},{"pmid":"35903534","id":"PMC_35903534","title":"TERT Promoter Mutations and Telomerase in Melanoma.","date":"2022","source":"Journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35903534","citation_count":40,"is_preprint":false},{"pmid":"32768523","id":"PMC_32768523","title":"TERT promoter mutations and GABP transcription factors in carcinogenesis: More foes than friends.","date":"2020","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/32768523","citation_count":39,"is_preprint":false},{"pmid":"35508454","id":"PMC_35508454","title":"KLF4 regulates TERT expression in alveolar epithelial cells in pulmonary fibrosis.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35508454","citation_count":38,"is_preprint":false},{"pmid":"32321884","id":"PMC_32321884","title":"BRAF and TERT promoter mutations: clinical application in thyroid cancer.","date":"2020","source":"Endocrine journal","url":"https://pubmed.ncbi.nlm.nih.gov/32321884","citation_count":38,"is_preprint":false},{"pmid":"19662126","id":"PMC_19662126","title":"Expansion and Harvesting of hMSC-TERT.","date":"2007","source":"The open biomedical engineering journal","url":"https://pubmed.ncbi.nlm.nih.gov/19662126","citation_count":37,"is_preprint":false},{"pmid":"32226942","id":"PMC_32226942","title":"TERT, a promoter of CNS malignancies.","date":"2020","source":"Neuro-oncology advances","url":"https://pubmed.ncbi.nlm.nih.gov/32226942","citation_count":35,"is_preprint":false},{"pmid":"24588324","id":"PMC_24588324","title":"TERT promoter mutation is uncommon in acral lentiginous melanoma.","date":"2014","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24588324","citation_count":35,"is_preprint":false},{"pmid":"29222734","id":"PMC_29222734","title":"TERT promoter hotspot mutations in breast cancer.","date":"2017","source":"Breast cancer (Tokyo, Japan)","url":"https://pubmed.ncbi.nlm.nih.gov/29222734","citation_count":34,"is_preprint":false},{"pmid":"33178686","id":"PMC_33178686","title":"Fisetin Promotes Hair Growth by Augmenting TERT Expression.","date":"2020","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33178686","citation_count":33,"is_preprint":false},{"pmid":"32882013","id":"PMC_32882013","title":"TERT and DNMT1 expression predict sensitivity to decitabine in gliomas.","date":"2021","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32882013","citation_count":31,"is_preprint":false},{"pmid":"31391125","id":"PMC_31391125","title":"TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAFV600E/TERT promoter double-mutated glioma.","date":"2019","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/31391125","citation_count":31,"is_preprint":false},{"pmid":"33946181","id":"PMC_33946181","title":"Significance of TERT Genetic Alterations and Telomere Length in Hepatocellular Carcinoma.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33946181","citation_count":31,"is_preprint":false},{"pmid":"31963842","id":"PMC_31963842","title":"CRISPR/Cas9-Mediated TERT Disruption in Cancer Cells.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31963842","citation_count":30,"is_preprint":false},{"pmid":"31662438","id":"PMC_31662438","title":"MED12, TERT and RARA in fibroepithelial tumours of the breast.","date":"2019","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31662438","citation_count":30,"is_preprint":false},{"pmid":"28835666","id":"PMC_28835666","title":"Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28835666","citation_count":30,"is_preprint":false},{"pmid":"36356143","id":"PMC_36356143","title":"TPP1 promoter mutations cooperate with TERT promoter mutations to lengthen telomeres in melanoma.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/36356143","citation_count":29,"is_preprint":false},{"pmid":"37532521","id":"PMC_37532521","title":"TERT promoter mutations in thyroid cancer.","date":"2023","source":"Endocrine journal","url":"https://pubmed.ncbi.nlm.nih.gov/37532521","citation_count":29,"is_preprint":false},{"pmid":"34559580","id":"PMC_34559580","title":"Autophagy, TERT, and mitochondrial dysfunction in hyperoxia.","date":"2021","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/34559580","citation_count":29,"is_preprint":false},{"pmid":"36901881","id":"PMC_36901881","title":"TERT Extra-Telomeric Roles: Antioxidant Activity and Mitochondrial Protection.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36901881","citation_count":29,"is_preprint":false},{"pmid":"11602347","id":"PMC_11602347","title":"Identification and analyses of the Xenopus TERT gene that encodes the catalytic subunit of telomerase.","date":"2001","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/11602347","citation_count":29,"is_preprint":false},{"pmid":"27667131","id":"PMC_27667131","title":"TRT, a Vertebrate and Protozoan Tc1-Like Transposon: Current Activity and Horizontal Transfer.","date":"2016","source":"Genome biology and evolution","url":"https://pubmed.ncbi.nlm.nih.gov/27667131","citation_count":27,"is_preprint":false},{"pmid":"26960334","id":"PMC_26960334","title":"High incidence of TERT mutation in brain tumor cell lines.","date":"2016","source":"Brain tumor pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26960334","citation_count":27,"is_preprint":false},{"pmid":"30392088","id":"PMC_30392088","title":"TERT promoter methylation is significantly associated with TERT upregulation and disease progression in pituitary adenomas.","date":"2018","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30392088","citation_count":27,"is_preprint":false},{"pmid":"26852175","id":"PMC_26852175","title":"Acquired TERT promoter mutations stimulate TERT transcription in mantle cell lymphoma.","date":"2016","source":"American journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/26852175","citation_count":26,"is_preprint":false},{"pmid":"34313327","id":"PMC_34313327","title":"Occurrence, functionality and abundance of the TERT promoter mutations.","date":"2021","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34313327","citation_count":24,"is_preprint":false},{"pmid":"22351525","id":"PMC_22351525","title":"TERT's role in colorectal carcinogenesis.","date":"2012","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/22351525","citation_count":24,"is_preprint":false},{"pmid":"35682861","id":"PMC_35682861","title":"Expression of Cellular and Extracellular TERRA, TERC and TERT in Hepatocellular Carcinoma.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35682861","citation_count":23,"is_preprint":false},{"pmid":"32117990","id":"PMC_32117990","title":"Expression of tert Prevents ALT in Zebrafish Brain Tumors.","date":"2020","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/32117990","citation_count":23,"is_preprint":false},{"pmid":"28407294","id":"PMC_28407294","title":"Altered TERT promoter and other genomic regulatory elements: occurrence and impact.","date":"2017","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28407294","citation_count":22,"is_preprint":false},{"pmid":"34724799","id":"PMC_34724799","title":"Tert-butylhydroquinone attenuates osteoarthritis by protecting chondrocytes and inhibiting macrophage polarization.","date":"2021","source":"Bone & joint research","url":"https://pubmed.ncbi.nlm.nih.gov/34724799","citation_count":22,"is_preprint":false},{"pmid":"31425705","id":"PMC_31425705","title":"Classifying Melanoma by TERT Promoter Mutational Status.","date":"2019","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/31425705","citation_count":21,"is_preprint":false},{"pmid":"32364535","id":"PMC_32364535","title":"Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer.","date":"2020","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/32364535","citation_count":21,"is_preprint":false},{"pmid":"27116373","id":"PMC_27116373","title":"Association mapping of caffeine content with TCS1 in tea plant and its related species.","date":"2016","source":"Plant physiology and biochemistry : PPB","url":"https://pubmed.ncbi.nlm.nih.gov/27116373","citation_count":21,"is_preprint":false},{"pmid":"33239622","id":"PMC_33239622","title":"Targeting the NCOA3-SP1-TERT axis for tumor growth in hepatocellular carcinoma.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33239622","citation_count":21,"is_preprint":false},{"pmid":"30591524","id":"PMC_30591524","title":"AGO2 promotes telomerase activity and interaction between the telomerase components TERT and TERC.","date":"2018","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/30591524","citation_count":20,"is_preprint":false},{"pmid":"36130485","id":"PMC_36130485","title":"GABP couples oncogene signaling to telomere regulation in TERT promoter mutant cancer.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36130485","citation_count":19,"is_preprint":false},{"pmid":"34395278","id":"PMC_34395278","title":"Clinical Application of TERT Promoter Mutations in Urothelial Carcinoma.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34395278","citation_count":18,"is_preprint":false},{"pmid":"25823555","id":"PMC_25823555","title":"HMGA2 expression pattern and TERT mutations in tumors of the vulva.","date":"2015","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/25823555","citation_count":18,"is_preprint":false},{"pmid":"32267900","id":"PMC_32267900","title":"Interplay between TERT promoter mutations and methylation culminates in chromatin accessibility and TERT expression.","date":"2020","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/32267900","citation_count":18,"is_preprint":false},{"pmid":"29693015","id":"PMC_29693015","title":"Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody.","date":"2018","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/29693015","citation_count":18,"is_preprint":false},{"pmid":"36815038","id":"PMC_36815038","title":"Melatonin alleviates alcoholic liver disease via EGFR-BRG1-TERT axis regulation.","date":"2022","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/36815038","citation_count":17,"is_preprint":false},{"pmid":"35460557","id":"PMC_35460557","title":"Imaging biomarkers of TERT or GABPB1 silencing in TERT-positive glioblastoma.","date":"2022","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35460557","citation_count":17,"is_preprint":false},{"pmid":"35783920","id":"PMC_35783920","title":"Understanding and managing the suppression of spermatogenesis caused by testosterone replacement therapy (TRT) and anabolic-androgenic steroids (AAS).","date":"2022","source":"Therapeutic advances in urology","url":"https://pubmed.ncbi.nlm.nih.gov/35783920","citation_count":17,"is_preprint":false},{"pmid":"16672457","id":"PMC_16672457","title":"Alicyclobacillus acidocaldarius thermophilic esterase EST2's activity in milk and cheese models.","date":"2006","source":"Applied and environmental microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/16672457","citation_count":17,"is_preprint":false},{"pmid":"37462445","id":"PMC_37462445","title":"TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type.","date":"2024","source":"The oncologist","url":"https://pubmed.ncbi.nlm.nih.gov/37462445","citation_count":17,"is_preprint":false},{"pmid":"32981294","id":"PMC_32981294","title":"Mechanisms of TERT Reactivation and Its Interaction with BRAFV600E.","date":"2020","source":"Endocrinology and metabolism (Seoul, Korea)","url":"https://pubmed.ncbi.nlm.nih.gov/32981294","citation_count":16,"is_preprint":false},{"pmid":"33741265","id":"PMC_33741265","title":"TERT Gene Fusions Characterize a Subset of Metastatic Leydig Cell Tumors.","date":"2021","source":"Clinical genitourinary cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33741265","citation_count":16,"is_preprint":false},{"pmid":"38141254","id":"PMC_38141254","title":"Whole tumor analysis reveals early origin of the TERT promoter mutation and intercellular heterogeneity in TERT expression.","date":"2024","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38141254","citation_count":16,"is_preprint":false},{"pmid":"28754720","id":"PMC_28754720","title":"TERT Promoter Hypermethylation in Gastrointestinal Cancer: A Potential Stool Biomarker.","date":"2017","source":"The oncologist","url":"https://pubmed.ncbi.nlm.nih.gov/28754720","citation_count":16,"is_preprint":false},{"pmid":"33520366","id":"PMC_33520366","title":"RBM10 regulates human TERT gene splicing and inhibits pancreatic cancer progression.","date":"2021","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/33520366","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45587,"output_tokens":6615,"usd":0.117993,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15580,"output_tokens":4093,"usd":0.090112,"stage2_stop_reason":"end_turn"},"total_usd":0.208105,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"hEST2/hTERT (TERT) was identified as the human telomerase catalytic subunit gene based on sequence similarity with lower eukaryote telomerase catalytic subunit genes; its mRNA expression parallels telomerase activity in tumor cells and during immortalization, suggesting it is a rate-limiting determinant of telomerase activity.\",\n      \"method\": \"Molecular cloning, sequence analysis, expression profiling in telomerase-positive vs. negative cell lines and tissues\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — foundational cloning and expression analysis replicated in the same study and confirmed by subsequent ectopic expression experiments (PMID:9528864); widely replicated across the field\",\n      \"pmids\": [\"9288757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Ectopic expression of epitope-tagged hTERT in telomerase-negative human cells reconstituted telomerase activity to levels comparable to immortal cells, and the expressed hTERT protein co-purified with cellular telomerase activity, establishing hTERT as the rate-limiting catalytic subunit of the telomerase holoenzyme.\",\n      \"method\": \"Ectopic expression of tagged hTERT, telomerase activity assay (TRAP), co-purification of hTERT with telomerase activity\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct reconstitution of telomerase activity by ectopic expression plus co-purification; functional validation in multiple cell lines\",\n      \"pmids\": [\"9528864\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Xenopus TERT (xTERT) reconstituted active telomerase in vitro when co-expressed with the Xenopus telomerase RNA (xTR) in a cell-free system, confirming that TERT is the catalytic reverse transcriptase subunit that directly assembles with the RNA component to form active telomerase. xTERT expression levels were shown to be the primary mechanism regulating telomerase activity during Xenopus development.\",\n      \"method\": \"In vitro reconstitution of telomerase activity using recombinant xTERT and xTR in rabbit reticulocyte lysate; telomerase activity assays across developmental stages\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro reconstitution with defined components; orthologous vertebrate TERT\",\n      \"pmids\": [\"11602347\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"In budding yeast (S. cerevisiae), a specific stem-loop hairpin within the telomerase RNA TLC1 is required for interaction with the Est2 (TERT ortholog) reverse transcriptase protein. Replacement of a 95-nucleotide region required for Est2 interaction with a 39-nucleotide pseudoknot from a distantly related telomerase RNA produced functional telomerase, indicating that Est2 associates with the RNA via a structured region rather than specific sequences.\",\n      \"method\": \"Mutagenesis of TLC1 RNA stem-loop structures; genetic complementation assays for telomere maintenance; RNA-protein interaction studies\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis combined with functional reconstitution in yeast; multiple orthogonal methods\",\n      \"pmids\": [\"15314178\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Human TERT interacts with RMRP RNA (the RNA component of mitochondrial RNA processing endoribonuclease) to form a distinct ribonucleoprotein complex with RNA-dependent RNA polymerase (RdRP) activity, producing double-stranded RNAs that can be processed into siRNA in a Dicer-dependent manner. This identifies a mammalian RdRP activity for TERT independent of telomere synthesis.\",\n      \"method\": \"Co-immunoprecipitation of TERT with RMRP RNA; in vitro RdRP activity assay; Dicer-dependent siRNA processing assay\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biochemical reconstitution of RdRP activity, Co-IP, and functional siRNA processing assay; published in Nature with multiple orthogonal methods\",\n      \"pmids\": [\"19701182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Recurrent somatic point mutations in the TERT core promoter (-124C>T and -146C>T) in melanoma generate de novo consensus binding motifs for ETS transcription factors and increase transcriptional activity from the TERT promoter by two- to fourfold in reporter assays, providing a mechanism for cancer-specific TERT re-expression.\",\n      \"method\": \"Systematic cancer genome sequencing; luciferase reporter assays of mutant vs. wild-type TERT promoter; ETS motif analysis\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reporter assays with functional validation; independently replicated by two concurrent papers (PMID:23348503 and PMID:23348506)\",\n      \"pmids\": [\"23348506\", \"23348503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TERT promoter mutations in urothelial cancer correlate with higher TERT mRNA levels, TERT protein levels, telomerase enzymatic activity, and telomere length compared to wild-type promoter cells, directly linking promoter mutation to functional telomerase upregulation.\",\n      \"method\": \"Analysis of 23 human UC cell lines: TERT mRNA quantification, TERT protein detection, telomerase TRAP assay, telomere length measurement\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal functional readouts (mRNA, protein, enzymatic activity, telomere length) in a well-defined cell line panel\",\n      \"pmids\": [\"25722414\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TERT promoter mutations lead to monoallelic expression of TERT in human cancer cells; hotspot TERT promoter mutations, without exception, re-activate only one allele as shown by deep RNA sequencing with allele-specific analysis.\",\n      \"method\": \"Deep RNA sequencing with allele-specific variant analysis in human cancer cell lines\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — single lab, allele-specific RNA-seq; technically rigorous but not independently replicated in this study\",\n      \"pmids\": [\"26657580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Nrf2 and TERT form a regulatory loop in glioblastoma: TERT knockdown abrogates Nrf2 levels, while ectopic Nrf2 expression increases TERT expression. TERT inhibition (by drug, siRNA, or dominant-negative TERT) suppresses expression and activity of pentose phosphate pathway enzymes G6PD and Transketolase, and leads to glycogen accumulation, placing TERT as a regulator of metabolic flux.\",\n      \"method\": \"siRNA knockdown, dominant-negative TERT overexpression, pharmacological inhibition (Costunolide), ectopic Nrf2 expression, enzyme activity assays, xenograft mouse model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple loss-of-function approaches plus rescue experiment, single lab, with in vivo validation\",\n      \"pmids\": [\"27148686\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"DNA hypermethylation of THOR (a 433-bp region immediately upstream of the TERT core promoter, containing 52 CpG sites) counteracts its repressive function on TERT promoter activity and constitutes a prevalent cancer-associated epigenetic mechanism of TERT upregulation independent of TERT promoter mutations.\",\n      \"method\": \"Reporter assays with methylated/unmethylated THOR constructs; bisulfite sequencing/methylation analysis in 1,352 human tumors; functional promoter activity assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reporter assays plus large-scale tumor methylation analysis with functional validation; multiple orthogonal methods\",\n      \"pmids\": [\"30358567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"AGO2 promotes telomerase activity and stimulates physical association between TERT and TERC; AGO2 depletion results in shorter telomeres and lower proliferation. AGO2 interacts with TERC and a small RNA (terc-sRNA) derived from the H/ACA box of TERC, and overexpression of terc-sRNA alone is sufficient to enhance telomerase activity.\",\n      \"method\": \"Gain- and loss-of-function approaches (AGO2 knockdown/overexpression); Co-IP of AGO2 with TERC; telomerase activity assay; telomere length measurement; in vitro and in vivo proliferation assays\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal functional assays with Co-IP, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"30591524\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ETS1 links BRAFV600E oncogenic signaling to TERT promoter activity in double-mutant (BRAFV600E + TERT promoter mutation) glioma: BRAF inhibition reduces ETS1 expression and phosphorylation, decreases TERT promoter activity and TERT expression exclusively in double-mutant cells. ChIP confirmed ETS1 binding to the mutant TERT promoter.\",\n      \"method\": \"qRT-PCR, chromatin immunoprecipitation (ChIP), Western blot, luciferase reporter assays, siRNA knockdown, BRAF inhibitor treatment in glioma cell lines\",\n      \"journal\": \"Acta neuropathologica communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter assays plus knockdown, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"31391125\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TERT promoter mutations create binding sites for the GABPB1L-isoform-containing GABP complex; increased binding of this specific complex to the mutant TERT promoter drives TERT reactivation and telomere maintenance. TERT promoter mutant GBM cells exhibit critical dependence on GABPB1L for proliferation, and GABPB1L knockdown combined with temozolomide impairs DNA damage response and reduces GBM tumor growth in vivo.\",\n      \"method\": \"GABPB1L-specific binding assays, GABPB1L knockdown (genetic/inducible), in vivo intracranial GBM tumor growth, combination with temozolomide chemotherapy\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic binding studies, inducible genetic knockdown, in vivo tumor model, multiple orthogonal methods in a single rigorous study\",\n      \"pmids\": [\"33758097\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CRISPR/Cas9-mediated base editing of the -124C>T TERT promoter mutation back to wild-type -124C blocked ETS family transcription factor binding to the TERT promoter, reduced TERT transcription and protein expression, and induced cancer cell senescence and proliferative arrest; local AAV delivery of the base editor inhibited growth of TERT promoter-mutant gliomas in vivo.\",\n      \"method\": \"Programmable adenine base editing (CjABE), sgRNA-guided CRISPR interference, qRT-PCR for TERT expression, Western blot for TERT protein, senescence assays, in vivo glioma xenograft model with AAV delivery\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — precision base editing with functional readouts (transcription, protein, senescence) plus in vivo validation; multiple orthogonal methods\",\n      \"pmids\": [\"32066906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"NCOA3 binds to the TERT promoter at the -234 to -144 region, recruits SP1, and transcriptionally activates TERT expression in hepatocellular carcinoma. NCOA3 knockdown suppresses HCC cell growth and is rescued by TERT overexpression, placing TERT downstream of the NCOA3-SP1 axis.\",\n      \"method\": \"NCOA3 knockdown/overexpression, TERT overexpression rescue, TERT promoter binding assays (ChIP-like), in vitro and in vivo tumor growth assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter binding assay, knockdown/rescue epistasis, single lab with multiple functional assays\",\n      \"pmids\": [\"33239622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TERT can transcriptionally activate a subclass of endogenous retroviruses (ERVs) independent of its telomerase activity, generating double-stranded RNAs sensed by the RIG-1/MDA5-MAVS pathway to trigger interferon signaling; TERT-induced ERV/interferon signaling stimulates CXCL10 chemokine expression, promoting infiltration of suppressive T-cell populations (CD4+ and FOXP3+) in tumors.\",\n      \"method\": \"ssGSEA across 9,264 tumor samples; TERT overexpression/knockdown; telomerase-dead TERT mutant; dsRNA detection; RIG-1/MDA5-MAVS pathway analysis; T-cell infiltration analysis\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — telomerase-dead mutant distinguishes telomere-independent function; multiple pathway analyses; single lab\",\n      \"pmids\": [\"35107856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Nuclear retention of TERT mRNA is driven by intron retention; specific introns are robustly retained in nuclear TERT transcripts (shown by single-molecule RNA FISH), and splicing of these retained introns occurs during mitosis. Blocking intron excision using RNA-targeting thiomorpholino antisense oligonucleotides forces nuclear retention and significantly affects cell viability.\",\n      \"method\": \"Single-molecule RNA FISH, RNA-targeting thiomorpholino antisense oligonucleotides (blocking intron excision), cell viability assays, splicing analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — single-molecule FISH for localization, antisense oligonucleotide functional perturbation; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"34083519\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"RBM10 promotes exclusion of exons 7 and 8 from hTERT pre-mRNA, switching production from full-length active hTERT (hTERT-FL) to a functionless isoform (hTERT-s), thereby suppressing telomerase activity and subsequent telomere shortening. RNA immunoprecipitation and RNA pull-down confirmed direct RBM10-hTERT RNA interaction.\",\n      \"method\": \"RNA immunoprecipitation (RNA-IP), RNA pull-down assay, gain/loss-of-function experiments, telomerase activity assay, xenograft tumor growth assay\",\n      \"journal\": \"American journal of cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA-IP and pull-down establish direct interaction; functional splicing switch confirmed by gain/loss-of-function; single lab\",\n      \"pmids\": [\"33520366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Missense TERT rare variants in MDS patients impair domain-specific functions including catalysis, protein-RNA interactions, and recruitment to telomeres, as assessed by a cell-based telomere elongation assay. A homology model of human TERT bound to shelterin protein TPP1 was used to infer structural impact of variants.\",\n      \"method\": \"Cloning of all rare missense variants; cell-based telomere elongation assay; homology structural modeling of TERT-TPP1 interaction\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic cell-based functional assays across many variants; homology model provides structural context; single lab\",\n      \"pmids\": [\"34019641\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GABP (specifically the GABPB1L isoform complex) couples EGFR-AMPK oncogenic signaling to TERT expression selectively from the mutant TERT promoter in glioblastoma; proliferation arrest decreases TERT expression in a GABP-dependent manner, and EGFR-AMPK signaling promotes telomerase activity and maintains telomere length.\",\n      \"method\": \"Copy number/mRNA/protein correlation analysis, pharmacologic EGFR inhibition, genetic GABP perturbation, AMPK pathway analysis, telomerase activity assay, telomere length measurement\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacologic and genetic perturbations with pathway epistasis; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"36130485\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TPP1 (ACD) promoter variants co-occurring with TERT promoter mutations in melanoma create or modify ETS transcription factor binding sites, increase TPP1 expression, and function together with TERT to synergistically lengthen telomeres, demonstrating that TERT promoter mutation alone is insufficient for telomere maintenance and requires cooperation with TPP1 upregulation.\",\n      \"method\": \"Genomic sequencing of melanoma samples, reporter assays for ACD promoter variants, TPP1/TERT expression analysis, telomere length measurement\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reporter assays plus telomere functional readout, mechanistic epistasis between TERT and TPP1, multiple orthogonal methods\",\n      \"pmids\": [\"36356143\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"KLF4 directly binds to the TERT promoter region (shown by ChIP) in alveolar epithelial cells and regulates TERT transcription; KLF4 siRNA knockdown reduces TERT expression and telomerase activity, while KLF4 overexpression increases them. In vivo, AAV-mediated KLF4 overexpression in alveolar epithelial cells protects TERT expression and suppresses pulmonary fibrosis.\",\n      \"method\": \"ChIP assay, siRNA knockdown, KLF4 overexpression, telomerase activity assay, AAV-mediated in vivo overexpression in mouse model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP establishes direct promoter binding, gain/loss-of-function with in vivo validation; single lab\",\n      \"pmids\": [\"35508454\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"A TERT activator compound (TAC) upregulates TERT transcription via the MEK/ERK/AP-1 signaling cascade. TAC-induced TERT elevation promotes telomere synthesis and silences p16INK4a expression via upregulation of DNMT3B-mediated promoter hypermethylation, reducing senescence markers, inflammatory cytokines, and neuroinflammation in aged mice while preserving cognitive function.\",\n      \"method\": \"TERT activator compound treatment; MEK/ERK/AP-1 pathway inhibitor epistasis; DNMT3B analysis; telomere synthesis assay; cellular senescence and p16INK4a measurements; in vivo aged mouse model\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — pathway epistasis with inhibitors, mechanistic downstream chromatin readout (DNMT3B-p16), in vivo validation with multiple aging hallmarks; published in Cell\",\n      \"pmids\": [\"38908367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TERT overexpression increases DNMT1 levels and DAC (decitabine) sensitivity via a telomerase-independent mechanism in glioma cells; p21 knockdown leads to TERT upregulation, and DNMT1 RNA inhibition abrogates DAC response in TERT-proficient cells, placing TERT upstream of DNMT1 in a p21-TERT-DNMT1 axis.\",\n      \"method\": \"TERT overexpression, p21 knockdown (siRNA), DNMT1 RNAi, DAC treatment, RNA sequencing, KEGG enrichment analysis\",\n      \"journal\": \"Neuro-oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with multiple knockdown/overexpression experiments and transcriptome analysis; single lab\",\n      \"pmids\": [\"32882013\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Genomic and epigenomic inactivation of EBF1 (via DNA methylation, dominant-negative mutations, or genomic deletion of EBF1 binding sites near the TERT promoter) de-represses TERT transcription in gastric cancer, identifying EBF1 as a direct TERT transcriptional repressor.\",\n      \"method\": \"Comprehensive genomic and epigenomic analysis of primary GCs; ChIP for EBF1 binding at TERT promoter; reporter assays; EBF1 knockdown/overexpression functional assays in vitro and in vivo\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP, reporter assays, functional epistasis with in vivo validation; multiple orthogonal methods in a single rigorous study\",\n      \"pmids\": [\"32364535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TERT silencing (directly or via GABPB1 knockdown) in TERT promoter mutant glioblastoma reduces pentose phosphate pathway flux, glucose-6-phosphate dehydrogenase activity, NADPH, lactate production, glycolytic flux, and glutathione levels, defining metabolic consequences of TERT suppression detectable by MRS.\",\n      \"method\": \"TERT and GABPB1 siRNA knockdown, 1H and hyperpolarized 13C MRS metabolic imaging, enzyme activity assays (G6PD), NADPH/NADH measurement, in vivo tumor imaging\",\n      \"journal\": \"Neuro-oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple metabolic assays with in vivo imaging; single lab with orthogonal MRS methods\",\n      \"pmids\": [\"35460557\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TERT is the catalytic reverse transcriptase subunit of the telomerase holoenzyme that assembles with the RNA component TERC to synthesize telomeric DNA repeats at chromosome ends; its expression is the rate-limiting determinant of telomerase activity, it is transcriptionally controlled by a network of factors including MYC, ETS/GABP (recruited by hotspot promoter mutations at -124/-146), KLF4, EBF1 (repressor), NCOA3-SP1, and epigenetic mechanisms (THOR methylation, chromatin accessibility), and it also possesses non-canonical functions including RdRP activity (via RMRP RNA complex), regulation of the pentose phosphate pathway and DNMT1 levels, ERV-driven immunosuppressive signaling, and mitochondrial protection against oxidative stress.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TERT is the catalytic reverse transcriptase subunit of telomerase, the ribonucleoprotein enzyme that synthesizes telomeric DNA repeats at chromosome ends, and its expression level is the rate-limiting determinant of telomerase activity during immortalization and tumorigenesis [#0, #1]. TERT directly assembles with the telomerase RNA component to form active enzyme, an interaction that depends on a structured region of the RNA rather than a specific sequence, as established by in vitro reconstitution and RNA-mutagenesis in vertebrate and yeast systems [#2, #3]. Because TERT is normally silenced in somatic cells, its cancer-specific re-expression is achieved chiefly through transcriptional deregulation: recurrent -124C>T and -146C>T promoter mutations create de novo ETS binding motifs and drive monoallelic reactivation, raising TERT mRNA, protein, telomerase activity, and telomere length [#5, #6, #7]. These mutant promoters are read out by the GABPB1L-isoform GABP complex and by ETS1, coupling oncogenic BRAF and EGFR-AMPK signaling to selective TERT induction and creating a dependence on GABPB1L for tumor growth that is reversible by base-editing the mutation back to wild-type [#11, #12, #13, #19]. A parallel layer of regulation operates through an activating network and repressive controls: KLF4, the NCOA3-SP1 axis, and MEK/ERK/AP-1 signaling activate TERT, while EBF1 acts as a direct repressor and THOR-region DNA methylation neutralizes repression to upregulate TERT independently of promoter mutation [#9, #14, #21, #22, #24]. Cooperation with the shelterin component TPP1, whose promoter variants co-occur with TERT promoter mutations, is required for productive telomere lengthening [#20]. Post-transcriptional control further tunes TERT through intron retention that confines transcripts to the nucleus until mitotic splicing and through RBM10-driven exon skipping that switches output toward a nonfunctional isoform [#16, #17]. Beyond telomere synthesis, TERT carries out telomerase-independent functions: it forms an RNA-dependent RNA polymerase complex with RMRP RNA generating Dicer-processed siRNAs [#4], transcriptionally activates endogenous retroviruses to trigger RIG-1/MDA5-MAVS interferon and CXCL10 signaling that shapes the tumor immune microenvironment [#15], sustains pentose phosphate pathway flux and an Nrf2 regulatory loop [#8, #25], and acts upstream of DNMT1 and DNMT3B to control DNA methylation and senescence programs [#22, #23]. Rare missense TERT variants in myelodysplastic syndrome impair catalysis, protein-RNA interaction, and telomere recruitment [#18].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established that TERT is itself the rate-limiting catalytic subunit of telomerase rather than a correlated marker, by showing its expression alone reconstitutes enzyme activity.\",\n      \"evidence\": \"Cloning and expression profiling, then ectopic expression of tagged hTERT with TRAP assays and co-purification in telomerase-negative cells\",\n      \"pmids\": [\"9288757\", \"9528864\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the structural basis of TERT-RNA assembly\", \"Did not address how TERT is silenced in somatic cells\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Defined how TERT engages telomerase RNA, showing assembly depends on a structured RNA region rather than specific sequence.\",\n      \"evidence\": \"In vitro reconstitution of vertebrate TERT with telomerase RNA in reticulocyte lysate, and stem-loop mutagenesis of yeast TLC1 with genetic complementation\",\n      \"pmids\": [\"11602347\", \"15314178\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Human TERT-TERC contact map not resolved at atomic level\", \"Did not address regulation of human TERT expression\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified the dominant mechanism of cancer-specific TERT reactivation, showing hotspot promoter mutations create ETS motifs that monoallelically upregulate telomerase and lengthen telomeres.\",\n      \"evidence\": \"Cancer genome sequencing, luciferase reporter assays, and a urothelial cell-line panel measuring mRNA, protein, TRAP activity, telomere length, plus allele-specific RNA-seq\",\n      \"pmids\": [\"23348506\", \"23348503\", \"25722414\", \"26657580\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Monoallelic specificity mechanism not fully explained\", \"Which trans-factors read the mutant motif left for later work\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Revealed a telomerase-independent activity by showing TERT forms an RdRP complex with RMRP RNA producing Dicer-processed siRNAs.\",\n      \"evidence\": \"Co-IP of TERT with RMRP RNA, in vitro RdRP assay, and Dicer-dependent siRNA processing\",\n      \"pmids\": [\"19701182\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological targets of the siRNAs not defined\", \"Relationship to telomerase complex assembly unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed which transcription factor complex executes promoter-mutant reactivation and that it is a therapeutic dependency, by linking the GABPB1L-GABP complex and ETS1 to oncogenic signaling and reverting the mutation by base editing.\",\n      \"evidence\": \"GABPB1L-specific binding and inducible knockdown, ChIP for ETS1, BRAF inhibition, and AAV-delivered adenine base editor in glioma models in vivo\",\n      \"pmids\": [\"33758097\", \"31391125\", \"32066906\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality across non-glioma promoter-mutant tumors not fully mapped\", \"Long-term safety of base-editing approach untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Expanded the transcriptional control network beyond promoter mutations, identifying activators (KLF4, NCOA3-SP1), a direct repressor (EBF1), and THOR methylation as a mutation-independent epigenetic route.\",\n      \"evidence\": \"ChIP, reporter assays, knockdown/rescue epistasis, large-scale tumor methylation analysis, and in vivo models across HCC, gastric, and lung tissue\",\n      \"pmids\": [\"30358567\", \"33239622\", \"35508454\", \"32364535\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Hierarchy and combinatorial logic among these factors unresolved\", \"Tissue specificity of each control mechanism incompletely defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed that promoter-mutant TERT upregulation is insufficient alone, requiring cooperative TPP1 upregulation for telomere lengthening.\",\n      \"evidence\": \"Melanoma genomic sequencing, ACD/TPP1 promoter reporter assays, and telomere length measurement\",\n      \"pmids\": [\"36356143\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other shelterin components similarly cooperate is unaddressed\", \"Mechanism of TERT-TPP1 functional synergy at telomeres not detailed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined post-transcriptional control of TERT through nuclear intron retention with mitotic splicing and RBM10-driven exon skipping toward a nonfunctional isoform.\",\n      \"evidence\": \"Single-molecule RNA FISH, antisense oligonucleotide blocking of intron excision, RNA-IP and pull-down, and telomerase activity assays\",\n      \"pmids\": [\"34083519\", \"33520366\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signals coupling splicing to cell cycle not identified\", \"Single-lab findings not independently replicated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Characterized telomerase-independent and downstream metabolic/epigenetic roles of TERT, linking it to PPP flux, an Nrf2 loop, ERV-driven interferon signaling, DNMT control, and senescence suppression.\",\n      \"evidence\": \"Loss/gain-of-function with telomerase-dead mutants, MRS metabolic imaging, pathway inhibitor epistasis, transcriptomics, and in vivo tumor and aging models\",\n      \"pmids\": [\"27148686\", \"35107856\", \"35460557\", \"32882013\", \"38908367\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular targets of TERT in these non-canonical roles not defined\", \"Mostly single-lab studies with limited cross-validation\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Connected TERT to human disease by showing rare missense variants impair catalysis, RNA binding, and telomere recruitment in MDS patients.\",\n      \"evidence\": \"Cell-based telomere elongation assays across all rare variants and homology modeling of TERT-TPP1\",\n      \"pmids\": [\"34019641\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Genotype-phenotype correlation in patients not fully established\", \"Structural inferences based on homology model rather than experimental structure\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the diverse telomerase-independent functions of TERT (RdRP, ERV/interferon signaling, metabolic and DNMT regulation) are mechanistically integrated with its canonical reverse transcriptase activity and partitioned across subcellular compartments remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unified model linking canonical and non-canonical activities\", \"Compartment-specific TERT pools and their distinct partners not defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [1, 2, 4]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [3, 4]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [1, 2]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [15, 23]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [16]},\n      {\"term_id\": \"GO:0005694\", \"supporting_discovery_ids\": [1, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [0, 1, 6]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [5, 12, 24]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [5, 13, 18]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [8, 25]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"complexes\": [\"telomerase holoenzyme\", \"TERT-RMRP RdRP complex\"],\n    \"partners\": [\"TERC\", \"RMRP\", \"TPP1\", \"AGO2\", \"GABPB1L\", \"RBM10\", \"SP1\", \"NCOA3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}